Hikma to divest rights to five drugs in exchange for acquiring new drugs
Hikma Pharmaceuticals must sell the rights to five generic injectable drugs to Amphastar Pharmaceuticals in order to acquire drug rights from Ben Venue Laboratories.
Hikma agreed to the divestitures under a...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch